Loss of heterozygosity analysis at different chromosome regions in wilms tumor confirms 1p allelic loss as a marker of worse prognosis: A study from the Italian association of pediatric hematology and oncology

Journal of Urology

Volumn 189, Issue 1, 2013, Pages 260-267

  Spreafico, Filippo ^a   Gamba, Beatrice ^a   Mariani, Luigi ^a   Collini, Paola ^a   D'Angelo, Paolo ^c   Pession, Andrea ^d   Di Cataldo, Andrea ^e   Indolfi, Paolo ^f   Nantron, Marilina ^g   Terenziani, Monica ^a   Morosi, Carlo ^a   Radice, Paolo ^a,b   Perotti, Daniela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c Pediatric Hematology Oncology   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g G GASLINI INSTITUTE   (Italy)

Author keywords

kidney neoplasms; loss of heterozygosity; pediatrics; Wilms tumor

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHROMOSOME 11P; CHROMOSOME 16Q; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 7P; CHROMOSOME ANALYSIS; DISEASE FREE SURVIVAL; DISEASE MARKER; HETEROZYGOSITY LOSS; HUMAN; MEDICAL SOCIETY; MICROSATELLITE MARKER; NEPHRECTOMY; NEPHROBLASTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

EID: 84870901266     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.09.009     Document Type: Article

References (25)

1. F. Spreafico, K. Pritchard Jones, M. Malogolowkin Treatment of relapsed Wilms tumor: lessons learned Expert Rev Anticancer Ther 9 2009 1807
2. D.M. Green, N.E. Breslow, J.B. Beckwith Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group J Clin Oncol 16 1998 237
3. J. de Kraker, N. Graf, H. van Tinteren Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial Lancet 364 2004 1229
4. P. Faria, J.B. Beckwith, K. Mishra Focal versus diffuse anaplasia in Wilms tumor - new definitions with prognostic significance: a report from the National Wilms Tumor Study Group Am J Surg Pathol 20 1996 909
5. G.M. Vujanic, B. Sandstedt, D. Harms Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood Med Pediatr Oncol 38 2002 79
6. P.E. Grundy, N.E. Breslow, S. Li Loss of heterozygosity for chromosome 1p and 16q is an adverse prognostic factor in favourable histology Wilms tumor: a report from the National Wilms Tumor Study Group J Clin Oncol 23 2005 7312
7. B. Klamt, M. Shulze, C. Thäte Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters Genes Chromosomes Cancer 22 1998 287
8. S. Wittmann, B. Zirn, M. Alkassar Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis Genes Chromosomes Cancer 46 2007 163
9. B. Messahel, R. Williams, A. Ridolfi Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study Eur J Cancer 45 2009 819
10. R.G. Grundy, J. Pritchard, P. Scambler Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour Oncogene 17 1998 395
11. R.M. Powlesland, A.K. Charles, K.T. Malik Loss of heterozygosity at 7p in Wilms' tumor development Br J Cancer 82 2000 323
12. D. Perotti, M.A. Testi, P. Mondini Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in Wilms tumours Genes Chromosomes Cancer 31 2001 42
13. E.J. Perlman, P.E. Grundy, J.R. Anderson WT1 mutation and 11P15 loss of heterozygosity predict relapse in very-low risk Wilms tumors treated with surgery alone: a Children's Oncology Group study J Clin Oncol 29 2011 698
14. S. Hing, Y.J. Lu, B. Summersqill Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors Am J Pathol 158 2001 393
15. Y.J. Lu, S. Hinq, R. Williams Chromosome 1q expression profiling and relapse in Wilms' tumour Lancet 360 2002 385
16. R. Natrajan, R.D. Williams, S.N. Hinq Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse J Pathol 210 2006 49
17. D. Perotti, F. Spreafico, F. Torri Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse Genes Chromosomes Cancer 7 2012 644
18. F. Spreafico, F.F. Bellani Wilms' tumor: past, present and (possibly) future Expert Rev Anticancer Ther 6 2006 249
19. D. Perotti, B. Gamba, M. Sardella Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors Oncogene 27 2008 4625
20. D. Perotti, G. De Vecchi, M.A. Testi Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14 Hum Mutat 24 2004 400
21. S. Holm A simple sequentially rejective Bonferroni test procedure Scand J Stat 6 1979 65
22. E.J. Perlman Pediatric renal tumors: practical updates for the pathologist Pediatr Dev Pathol 8 2005 320
23. D.M. Green, N.E. Breslow, J.B. Beckwith Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study J Clin Oncol 11 1993 91
24. K. Pritchard-Jones, A. Kelsey, G. Vujanic Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilms' Tumor Working Group J Clin Oncol 21 2003 3269
25. S.T. Sredni, S. Gadd, C.C. Huang Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features Clin Cancer Res 15 2009 6008